bf/NASDAQ:ALZN_icon.jpeg

NASDAQ:ALZN

Alzamend Neuro, Inc.

  • Stock

USD

Last Close

2.52

06/11 21:32

Market Cap

3.52M

Beta: -

Volume Today

118.56K

Avg: 184.60K

PE Ratio

−0.38

PFCF: −0.69

    Description

    Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder...Show More

    Earnings

    Earnings per Share (Estimate*)

    -10-52019-01-302020-01-302021-01-312022-09-132024-03-21

    Revenue (Estimate*)

    0.000.000.010.010.012019-01-302020-01-302021-01-312022-09-132024-03-21

    *Estimate based on analyst consensus